Fingolimod for Multiple Sclerosis: Mechanism of Action, Clinical Outcomes, and Future Directions

Article

DOI: 10.1007/s11910-011-0216-9

Cite this article as:
Mehling, M., Kappos, L. & Derfuss, T. Curr Neurol Neurosci Rep (2011) 11: 492. doi:10.1007/s11910-011-0216-9

Abstract

The oral sphingosine 1-phosphate receptor (S1PR) modulator fingolimod functionally antagonizes S1PR hereby blocking lymphocyte egress from secondary lymphoid organs to the peripheral blood circulation. This results in a reduction in peripheral lymphocyte counts, including potentially encephalitogenic T cells. In patients with relapsing multiple sclerosis fingolimod has been shown to be an effective treatment. In phase 2 and phase 3 studies fingolimod-treated patients had reduced disease activity clinically and in MRI. Although severe infectious complications occurred in single cases treated with fingolimod, the frequency of overall infections was comparable in fingolimod-treated patients and controls. Overall, in clinical studies fingolimod was well tolerated and had a favorable safety profile. In follow-up studies with continuous fingolimod, treatment showed sustained efficacy while being well tolerated.

Keywords

Multiple sclerosis MS Therapy Fingolimod FTY720 T cell TRANSFORMS FREEDOMS 

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Matthias Mehling
    • 1
    • 2
  • Ludwig Kappos
    • 1
    • 3
  • Tobias Derfuss
    • 1
    • 3
  1. 1.Department of Neurology and Department of BiomedicineUniversity Hospital BaselBaselSwitzerland
  2. 2.Immunobiology Laboratory, Department of Biomedicine and Medical Outpatient DepartmentUniversity Hospital BaselBaselSwitzerland
  3. 3.Clinical Neuroimmunology Laboratory/Department of BiomedicineUniversity Hospital BaselBaselSwitzerland

Personalised recommendations